Island Pharmaceuticals Limited (ASX:ILA)

Market Cap	30.69M
Revenue (ttm)	399.37K
Net Income (ttm)	-3.24M
Shares Out	236.09M
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	630,298
Average Volume	632,525
Open	0.1350
Previous Close	0.1300
Day's Range	0.1350 - 0.1550
52-Week Range	0.0580 - 0.2800
Beta	0.09
RSI	35.31
Earnings Date	Aug 25, 2025

About Island Pharmaceuticals

Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections in Australia and the United States of America. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a collaboration agreement with Monash University and National Cancer Institute IND. It also has a cooperative research and development agreement with the U.S. Army, Island in preparation for its Pha...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ILA